Hims & Hers: The playbook for building a $1.5B DTC telehealth platform

Bottom line: Hims & Hers transformed from a stigma-busting men's health startup in 2017 into a $1.48 billion revenue (2024), 2.4 million subscriber vertically integrated healthcare platform achieving its first profitable year in 2024. The company's success stems from three core pillars: owning the entire value chain from consultation to pharmacy fulfillment, relentless focus on personalization driving 85%+ retention, and disciplined unit economics maintaining <1-year payback periods on customer acquisition. For a Brazilian telemedicine entrant, Hims demonstrates that vertical integration—particularly pharmacy ownership—creates both margin protection and competitive moats, while subscription-first economics and multi-condition expansion enable scalable, predictable revenue growth.

1. Executive summary: Seven insights for the Brazilian executive

This section distills the most actionable strategic findings for a VP of Sales/Revenue Operations launching a telemedicine subsidiary in Brazil.

1. Vertical integration is non-negotiable for margin protection. Hims achieved 79% gross margins in 2024 by owning affiliated pharmacies and a 503B compounding facility. Third-party pharmacy relationships erode margins and create supply chain vulnerability—Hims' pharmacy ownership was the primary enabler of their GLP-1 strategy.

2. Subscription economics trump transaction models. With 91% recurring revenue from subscriptions at IPO and 85%+ long-term retention, Hims built predictable revenue that scales. The subscription model enables aggressive CAC investment while maintaining <1-year payback periods.

3. Personalization drives retention, not price. Moving 55%+ of subscribers to personalized treatment plans delivered 10-20+ point retention improvements across categories. CEO Andrew Dudum: "What we are building is possibly the most powerful dataset in healthcare because it's the only at-scale, fully verticalized end-to-end system."

4. Start with stigmatized conditions, expand methodically. Hims launched in ED and hair loss—conditions men avoided discussing with doctors. This created word-of-mouth growth and organic acquisition. Only after proving unit economics did they expand into dermatology, mental health, and weight loss.

5. Marketing efficiency improves with scale and brand. Marketing spend dropped from 51% of revenue (2022) to 39% (Q1 2025)—a dramatic improvement while absolute spend increased 76%. Organic and lower-cost channels now drive an increasing share of new customers.

6. The GLP-1 opportunity is massive but regulatory-dependent. Weight loss reached $225M revenue in 2024 (from zero), but FDA regulatory changes created significant near-term volatility. Any weight loss strategy must account for regulatory cliffs.

7. Speed beats perfection in early stages. Dudum: "Pre-Series A things were chaotic—the product wasn't perfect, shipping was unreliable—but we had confidence in demand. That nugget was incredibly valuable." Prove demand before investing in infrastructure.

2. Company overview: From stigma-fighting startup to healthcare platform

Founding thesis and early traction

Hims & Hers was founded in November 2017 in San Francisco by Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector, incubated at Atomic Labs (a venture studio backed by Peter Thiel and Marc Andreessen). The founding insight: 74% of the US population (Millennials and Gen X) had limited loyalty to the existing healthcare system and avoided doctors for stigmatized conditions.

The initial product—branded erectile dysfunction and hair loss treatments delivered discreetly to your door—generated explosive early demand. Within three years, the company built:

• A digitally native consumer brand destigmatizing sensitive health topics
• A distributed network of 240+ licensed providers
• A proprietary EMR system with diagnostic algorithms
• An affiliated mail-order pharmacy (XeCare, Ohio)

Timeline of key milestones

Business model architecture

Hims operates a fully verticalized DTC healthcare platform with four integrated layers:

Layer 1: Consumer Brand & Digital Front-End

• Hims (men's health) and Hers (women's health) consumer brands
• Mobile and web platforms optimized for millennial/Gen X demographics
• 24/7 digital access, asynchronous consultations in most states

Layer 2: Provider Network

• 400+ contracted licensed healthcare providers (MDs, DOs, NPs, PAs)
• Providers credentialed through affiliated "You Health" medical groups
• Average consultation cost: $39 (vs. $200-300 traditional in-person)
• Health system partnerships (Ochsner, Mount Sinai, Carbon Health) for in-person referrals

Layer 3: Proprietary Technology Stack

• Custom EMR with automated SOAP notes and risk flagging
• MedMatch AI platform providing data-driven treatment recommendations
• 6.7+ million secure messages exchanged with care teams annually
• 75% of messages receive responses within 5 hours

Layer 4: Pharmacy Fulfillment

• 503A pharmacies (patient-specific compounding): XeCare (Ohio, 300K sq ft), Apostrophe (Arizona, 25K sq ft)
• 503B outsourcing facility (batch manufacturing): MedisourceRx (California, acquired Sept 2024)
• 70+ pharmacists, ~150 pharmacy technicians
• Central Ohio location enables 1-day shipping to 60% of US population
• Third-party partners (PostMeds, Capsule, Alto) for overflow and same-day delivery

Current market position

Hims commands an estimated 47% market share in DTC telehealth, roughly 3x larger than nearest competitor Ro. The company operates across seven specialty categories:

3. Unit economics analysis: How Hims built profitable growth

Core unit economics evolution

The transformation of Hims' unit economics from startup to profitability illustrates disciplined growth investing.

Customer Acquisition Cost (CAC)

Key insight: Rising CAC reflects deliberate investment in higher-value customers across more categories—not deteriorating efficiency. Management maintains strict discipline: "We have upheld our rigorous capital allocation standards inclusive of a payback period of less than a year on marketing investments" (CFO Yemi Okupe, Q1 2025).

LTV and LTV:CAC Metrics

Average Revenue Per User (ARPU) Trajectory

The 50%+ ARPU growth from 2023-2025 reflects GLP-1 weight loss products (higher price points) and successful cross-selling into multiple conditions. CFO Yemi Okupe noted that 20%+ of subscribers now have multi-specialty relationships with the platform.

Gross margin structure and evolution

Hims has maintained industry-leading gross margins through vertical integration:

Why margins compressed in 2024-2025: The GLP-1 weight loss business, while highly accretive to revenue, operates at lower margins due to shorter shipping cadences and injectable product costs. CFO Okupe: "Lower margins are a common dynamic we often see early in an offering's life cycle... we expect to optimize unit economics through verticalization, process improvements, and logistics optimization."

Retention and churn dynamics

Retention is Hims' most critical metric—the foundation of their subscription economics.

Overall Platform Retention:

• Long-term revenue retention: >85% (company target)
• Subscriber retention improvement from personalization: 10-20+ percentage points in key categories

Retention by Product Category (from earnings calls):

CMO Dr. Patrick Carroll on GLP-1 engagement: "At 4 weeks, 85% of GLP-1 patients are engaging with the platform... By 12 weeks, 70% are continuing. That's a 30-point delta in clinical adherence versus traditional brick-and-mortar."

Cohort economics by product category

While Hims doesn't fully disclose cohort-level P&L by category, management commentary reveals relative economics:

Strategic insight: Weight loss customers have the highest cross-sell potential. Q3 2024: "20,000 weight loss subscribers were pre-existing customers" and "20% of weight loss subscribers have multi-specialty relationships."

Marketing efficiency as key operating leverage

The most significant unit economics improvement has been marketing efficiency:

Drivers of marketing leverage (CFO Okupe):

1. "Retention gains from shift toward personalized solutions"
2. "Dramatically raised the bar for marketing investment quality"
3. "More subscribers through organic and lower-cost channels"
4. "Entry into specialties more conducive to word-of-mouth referrals"

Management guides to 1-3 points of annual marketing leverage going forward, targeting 20% adjusted EBITDA margin by 2030.

4. Revenue operations deep dive: Building the subscription engine

Revenue organization structure

Based on SEC filings and public disclosures, Hims organizes its revenue operations across several functional areas:

Key Executives:

• CFO Yemi Okupe: Former Divisional CFO at Uber (UberEats, Global Mobility), prior experience at eBay, PayPal/Braintree, Google. Leads financial planning, forecasting, and investor relations.
• COO Mike Chi: 20+ years in consumer businesses, leads brand positioning, growth marketing, and operations.
• CPO Dheerja Kaur (joined July 2025): Former VP Product at Robinhood (led Gold subscription to 3M+ subscribers).

Revenue Composition:

• Online Revenue: 98.3% (subscriptions + one-time purchases)
• Wholesale Revenue: 1.7% (CVS, Walgreens, retail partners)

Customer lifecycle management approach

Hims has built a sophisticated lifecycle management system centered on their proprietary EMR and MedMatch AI:

Acquisition Phase:

• Multi-channel paid marketing (declining as % of spend)
• Organic/SEO increasingly important
• Word-of-mouth from existing customers
• Dynamic intake questionnaires adjusted by condition

Onboarding Phase:

• Identity verification (digital photo/ID check)
• Medical chart creation in proprietary EMR
• Provider consultation (async or video depending on state)
• Prescription issuance and fulfillment

Engagement Phase (Critical for Retention):

• CMO Carroll: "At 4 weeks, patients have typically had at least 3 engagements with the provider. By 12 weeks, an average of 5 engagements."
• Post-titration: "Providers still engage with patients on average of at least once a month."
• 6.7+ million secure messages exchanged annually
• 75% of messages receive responses within 5 hours

Retention Phase:

• Personalization drives retention: 55%+ of subscribers now on personalized solutions
• Multi-condition cross-sell: 300,000+ subscribers treated for 2+ conditions
• Snooze/reactivation options between billing periods

Reactivation:

• Q3 2024: "20,000 subscribers that acquired a weight loss solution were pre-existing customers"—demonstrating effective reactivation through new category launches

Revenue forecasting and predictability

Hims has established strong forecasting credibility by consistently beating guidance:

Track Record vs. Projections:

CFO Okupe on forecasting approach: "Our team's track record of delivering against ambitious goals quarter after quarter gives us the confidence to share these targets."

Revenue predictability drivers:

1. High subscription mix (91%+ at IPO, similar today)
2. Strong retention (85%+)
3. Visible cohort economics
4. Multi-month billing cadences (30-360 days depending on product)

Technology infrastructure for RevOps

Proprietary EMR System:

• Central hub for all patient data
• Automated SOAP note generation
• Flags high-risk findings for provider attention
• Structured data enables care pathway optimization

MedMatch AI Platform:

• Launched 2023, expanded throughout 2024
• Analyzes de-identified data from thousands of patient interactions
• Provides data-driven treatment recommendations to providers
• Intelligent routing capabilities
• Goal: "Identify most effective treatment first time"

CEO Dudum on data advantage: "We are overseeing and managing not only the initial patient intake, but the diagnostic component, the treatment component, the long-term relationship, the chronic care, the adjustment to treatment, and ultimately, whether or not the outcome is delivered."

Note on CRM/RevOps tooling: Hims has not publicly disclosed specific CRM, marketing automation, or RevOps tooling vendors. Their proprietary EMR appears to serve as the central customer data platform.

5. Growth playbook: How Hims scaled category by category

Revenue progression and key inflection points

Key inflection points:

1. 2020: Pharmacy ownership – XeCare facility unlocked margin improvement and supply chain control
2. Q4 2022: EBITDA profitability – Proved business model viability at scale
3. 2024: GLP-1 launch – Weight loss contributed $225M in first full year, driving ARPU from $53 to $73

Category expansion sequencing logic

Hims followed a deliberate sequence for category expansion:

Phase 1: Stigmatized Core (2017-2019)

• ED and hair loss: Conditions men avoided discussing with doctors
• Created strong brand identity and word-of-mouth growth
• Established unit economics benchmarks

Phase 2: Gender Expansion (2018-2019)

• Hers brand for women's health (birth control, skincare)
• Leveraged same infrastructure for new demographic

Phase 3: Condition Adjacency (2019-2021)

• Mental health (anxiety/depression): Natural cross-sell from existing customers
• Dermatology (Apostrophe acquisition): Higher ARPU, strong retention

Phase 4: High-ARPU Categories (2023-present)

• Weight loss: $199/month GLP-1 vs. $30-50 for legacy categories
• Labs/diagnostics: Enabling more personalized treatment plans
• Future: Low testosterone, menopause, cardiovascular

CEO Dudum's expansion philosophy: "Before you build it, prove it. Create 'coming soon' landing pages to gauge customer interest. Use waiting lists to quantify demand before product development."

Marketing channel evolution

Early Phase (2017-2020): Paid Media Dominance

• Heavy investment in paid social, search, and display
• Marketing as ~50%+ of revenue
• Focus on brand awareness and destigmatization messaging

Growth Phase (2021-2023): Efficiency Focus

• Shifted toward higher-intent channels
• Built proprietary content and SEO
• Marketing dropped to 45-46% of revenue

Mature Phase (2024-present): Organic Flywheel

• Q1 2025: Marketing at 39% of revenue (record efficiency)
• Increasing organic and word-of-mouth acquisition
• CFO: "More subscribers through organic and lower-cost channels as a result of historical investments in our brand"

Dudum on channel strategy: "We wanted to own as much of our marketing and as many proprietary channels as possible... Building brands solely on platforms like Instagram is no longer viable."

Path to profitability milestones

Profitability driver breakdown:

• Marketing leverage: 51% → 39% of revenue (12 points over 3 years)
• Gross margin optimization: 76% → 79% (2021-2023, before GLP-1 mix shift)
• Operating leverage across technology and G&A
• Scale benefits in pharmacy operations

6. Operational infrastructure: Building the healthcare machine

Pharmacy operations deep dive

503A Facilities (Patient-Specific Compounding):

• Total footprint: ~700,000 sq ft (with additional 350,000 sq ft under construction)
• Staffing: 70+ pharmacists, ~150 pharmacy technicians
• Capabilities: Personalized dosage adjustments, allergen removal, multi-medication combinations

503B Facility (FDA-Registered Sterile Compounding):

• FDA-registered, follows cGMP regulations
• USP 797 compliant for sterile compounding
• HEPA filtration cleanrooms, environmental monitoring
• Enables batch production of compounded medications

Quality assurance protocols:

1. Active ingredients verified against USP specifications
2. Third-party analytical lab testing for potency verification
3. FDA-inspected lab blind tests on dispensed medications
4. Certificates of Analysis (COA) available to customers
5. Pharmaceutical-grade ingredients from FDA-registered facilities

Telemedicine consultation layer

Care Delivery Model (Primarily Asynchronous):

Provider Network:

• 400+ contracted licensed healthcare providers (MDs, DOs, NPs, PAs)
• Providers credentialed through affiliated "You Health" medical groups
• Board-certified, licensed in patient's state
• Not employed—contracted through medical group structure

Technology stack summary

Regulatory compliance approach

State Licensing:

• Providers licensed in every state where patients are served
• Platform operates through affiliated medical group structure
• Both async and sync consultations offered per state requirements
• 50-state + D.C. coverage achieved

Pharmacy Regulations:

• 503A: Regulated by state Boards of Pharmacy
• 503B: FDA cGMP regulations, USP 797 compliance
• Active ingredients from FDA-registered facilities

Controlled Substances:

• DEA registration per state
• Leverages telemedicine flexibilities (extended through December 31, 2026)
• Audio-video consultations for Schedule II-V where required

GLP-1 Regulatory Status:

• Semaglutide shortage resolved by FDA (February 2025)
• Company pivoted away from commercially available dosages
• Continuing "personalized" doses where clinically necessary
• Focus shifting to liraglutide (generic) and oral alternatives

7. Lessons and warnings: What Hims got wrong

Challenges discussed in earnings calls

GLP-1 Regulatory Cliff: The FDA declared the semaglutide shortage resolved in February 2025, creating significant near-term volatility.

CFO Okupe (Q1 2025): "We expect to complete the transition of subscribers previously on commercially available dosages of semaglutide to either appropriate alternatives on our platform or other platforms entirely by the end of the second quarter. This transition is expected to result in a one-time quarter-over-quarter revenue drop."

Sexual Health Transition Volatility: CFO Okupe (Q1 2025): "As we transition our subscriber base toward more premium daily products, we expect some volatility in Sexual Health growth as we recalibrate our approach to messaging and invest in consumer education."

Gross Margin Pressure from New Products: CFO Okupe (Q3 2024): "Gross margin declined 2 points quarter-over-quarter... Scaling of the weight loss specialty was the primary driver. Lower margins are a common dynamic we often see early in an offering's life cycle."

Branded Medication Sourcing Challenge: CEO Dudum (Q4 2024): "We still really can't actually source the branded medications from our pharmacies for our own platform. There's a limited supply in a way that prevents us from having any durable offering at the scale that we offer it."

Three big mistakes from CEO Andrew Dudum

In a Cherubic Ventures AMA, Dudum candidly shared three key learnings:

1. Hired Wrong People at Wrong Time:

"It's important to be aware of what your company needs and to hire proportional to those needs. Not too senior in the early days when scrappiness is needed."

2. Don't Outsource Your Brand:

"If you want to build a brand that's unique and special, it needs to come from you. Not a fancy and expensive agency."

3. Focus on Uncovering Demand First:

"Pre-Series A things were chaotic—the product wasn't perfect, shipping and operations were unreliable. But we had confidence there was significant demand for what we were building, and that nugget was incredibly valuable."

Post-COVID normalization

While Hims benefited from COVID-era telehealth adoption, management navigated normalization by:

• Maintaining investment discipline (payback period <1 year)
• Diversifying into new categories (weight loss)
• Building brand for long-term organic growth
• Achieving profitability to reduce dependency on external capital

Competitive moat erosion

DrugPatentWatch analysis (January 2026) highlighted a key warning: "Competitive moats erode when manufacturers standardize access across telehealth channels"—referring to Novo Nordisk offering identical Wegovy pricing ($499/month) to multiple platforms simultaneously.

8. Strategic implications for Brazil 2026: Applying the Hims playbook

What translates to Brazil

1. Vertical Integration Creates Defensibility

Hims' greatest strategic advantage is owning pharmacy operations. For a Brazilian entrant:

• Consider early investment in affiliated pharmacy/compounding infrastructure
• Pharmacy ownership provides margin protection (Hims: 79% gross margin vs. ~30-40% typical pharmacy)
• Supply chain control becomes critical for high-demand products

2. Start with Stigmatized Conditions

Hims proved that stigmatized health conditions (ED, hair loss) create:

• Strong word-of-mouth growth (customers share privately)
• Lower competitive intensity (traditional providers underserve)
• High customer loyalty and retention

Brazil has similar dynamics—identify conditions where patients avoid traditional healthcare due to stigma or inconvenience.

3. Subscription-First Economics

Key metrics to target:

• 90%+ recurring revenue from subscriptions
• <1 year payback period on customer acquisition
• 80%+ subscriber retention
• 3x+ LTV:CAC ratio

4. Personalization Drives Retention

Hims saw 10-20+ point retention improvements from personalized treatment plans. Invest early in:

• Data infrastructure to enable personalization
• Provider training on personalization protocols
• Technology for treatment matching

What requires adaptation

1. Regulatory Environment

Brazil's ANVISA regulations and telehealth framework differ significantly from US FDA/state licensing:

• Understand compounding pharmacy regulations (RDC 67/2007 for Brazil)
• Navigate CRM registration requirements for physicians
• Adapt consultation requirements to Brazilian telehealth rules

2. Payment Infrastructure

Unlike Hims' cash-pay model (no insurance), Brazil's SUS and private insurance landscape may require different approaches:

• Consider hybrid cash-pay and insurance models
• Evaluate installment payment options (common in Brazilian e-commerce)
• Build relationships with private health insurers

3. Category Prioritization

While ED and hair loss may work in Brazil, evaluate:

• Weight loss (strong demand, but regulatory complexity with GLP-1s)
• Mental health (growing awareness, potential telehealth fit)
• Women's health (birth control access, menopause support)
• Chronic disease management (diabetes, hypertension)

4. Marketing Channel Mix

Brazil's digital landscape differs from US:

• WhatsApp may be more important than email
• Instagram/TikTok engagement patterns differ
• Consider influencer and pharmacy partnerships

Recommended first-year priorities

Based on Hims' early playbook, prioritize in Year 1:

Financial benchmarks from Hims trajectory

For the Brazilian subsidiary, target these benchmarks based on Hims' progression:

Key quotes for leadership alignment

On growth philosophy (CEO Dudum):

"Every day is day 1—even as a public company. I meet with all product managers regularly. We are constantly testing and iterating on new ideas."

On unit economics discipline (CFO Okupe):

"We have upheld our rigorous capital allocation standards inclusive of a payback period of less than a year on marketing investments."

On customer experience (CEO Dudum):

"When I look at healthcare, there's no part of the experience that I love. It's a cold experience, not personalized to you at all, wastes your time and money, and makes you feel sick. In the next 10 years, that's going to change."

On competitive moats (CEO Dudum):

"What we are building is possibly the most powerful dataset in healthcare because it's the only at-scale, fully verticalized end-to-end system."

Appendix: Key data tables and quotes

Financial summary table (2020-2025)

Quarterly revenue progression (2024-2025)

Key management quotes by topic

On Personalization:

"With greater customization for individual clinical needs at affordable prices, we are seeing retention drift higher across many of our specialties." — CFO Okupe

On Long-term Vision:

"10 million subscribers on the platform feels really quite in reach. My optimistic hope would be to achieve this in the next five to six years." — CEO Dudum

On Data Moat:

"We're overseeing not only the initial patient intake, but the diagnostic component, treatment, long-term relationship, chronic care, adjustment to treatment, and ultimately, whether or not the outcome is delivered." — CEO Dudum

On Marketing Efficiency:

"Higher retention as a result of an increasing shift to personalization as well as acquisition of customers organically and through lower cost channels continues to provide confidence in our ability to achieve between 1 to 3 points of leverage on marketing spend per annum." — CFO Okupe

On Regulatory Philosophy:

"We aim in all of our adventures to be extremely blue chip and play by the rules." — CEO Dudum

On Building the Company:

"Execute and learn quickly, then build and perfect later." — CEO Dudum

2030 Financial Targets